{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=T+cells&page=62",
    "query": {
      "intervention": "T cells",
      "page": 62
    },
    "page_size": 10
  },
  "pagination": {
    "page": 62,
    "page_size": 10,
    "total_count": 3575,
    "total_pages": 358,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=T+cells&page=63&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=T+cells&page=61&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-17T06:38:19.911Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02153580",
      "title": "Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma",
        "B-Cell Prolymphocytic Leukemia",
        "High Grade B-Cell Lymphoma, Not Otherwise Specified",
        "Post-Transplant Lymphoproliferative Disorder",
        "Recurrent Adult Burkitt Lymphoma",
        "Recurrent Chronic Lymphocytic Leukemia",
        "Recurrent Diffuse Large B-Cell Lymphoma",
        "Recurrent Follicular Lymphoma",
        "Recurrent Hairy Cell Leukemia",
        "Recurrent Lymphoplasmacytic Lymphoma",
        "Recurrent Mantle Cell Lymphoma",
        "Recurrent Marginal Zone Lymphoma",
        "Recurrent Small Lymphocytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bendamustine Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine Phosphate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2014-10-14",
      "completion_date": "2027-08-11",
      "has_results": false,
      "last_update_posted_date": "2026-10-26",
      "last_synced_at": "2026-11-17T06:38:19.911Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02153580"
    },
    {
      "nct_id": "NCT01994382",
      "title": "Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Follicular Lymphoma (FL/Indolent NHL)",
        "Aggressive NHL (a NHL)",
        "Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)",
        "T-cell Lymphoma (PTCL and CTCL)",
        "B-cell Non Hodgkin Lymphoma (NHL)"
      ],
      "interventions": [
        {
          "name": "Cerdulatinib",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 260,
      "start_date": "2013-08-30",
      "completion_date": "2020-12-15",
      "has_results": true,
      "last_update_posted_date": "2022-04-05",
      "last_synced_at": "2026-11-17T06:38:19.911Z",
      "location_count": 23,
      "location_summary": "Huntsville, Alabama • Gilbert, Arizona • Los Angeles, California + 20 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01994382"
    },
    {
      "nct_id": "NCT00003961",
      "title": "Sargramostim After Bone Marrow Transplantation in Treating Patients With Myelodysplastic Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Diseases"
      ],
      "interventions": [
        {
          "name": "sargramostim",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": null,
      "start_date": "1999-04",
      "completion_date": "2007-12",
      "has_results": false,
      "last_update_posted_date": "2014-04-17",
      "last_synced_at": "2026-11-17T06:38:19.911Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003961"
    },
    {
      "nct_id": "NCT00132691",
      "title": "Multicenter Uveitis Steroid Treatment (MUST) Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Uveitis"
      ],
      "interventions": [
        {
          "name": "fluocinolone acetonide intraocular implant",
          "type": "DRUG"
        },
        {
          "name": "oral corticosteroid with immunosuppressive agents as needed",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "JHSPH Center for Clinical Trials",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 255,
      "start_date": "2005-09",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2016-11-25",
      "last_synced_at": "2026-11-17T06:38:19.911Z",
      "location_count": 21,
      "location_summary": "La Jolla, California • Los Angeles, California • San Francisco, California + 16 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00132691"
    },
    {
      "nct_id": "NCT00060424",
      "title": "Fludarabine Phosphate and Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "B-Cell Prolymphocytic Leukemia",
        "Chronic Lymphocytic Leukemia",
        "Prolymphocytic Leukemia",
        "Recurrent Chronic Lymphocytic Leukemia",
        "Recurrent Small Lymphocytic Lymphoma",
        "Refractory Chronic Lymphocytic Leukemia",
        "T-Cell Prolymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "Cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Hematopoietic Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        },
        {
          "name": "Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Total-Body Irradiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2003-03",
      "completion_date": "2010-09-22",
      "has_results": true,
      "last_update_posted_date": "2017-12-08",
      "last_synced_at": "2026-11-17T06:38:19.911Z",
      "location_count": 2,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00060424"
    },
    {
      "nct_id": "NCT01081223",
      "title": "Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Glioma",
        "High Grade Astrocytoma",
        "Glioblastoma Multiforme"
      ],
      "interventions": [
        {
          "name": "Cancer vaccine plus immune adjuvant",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "TVAX Biomedical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2010-04",
      "completion_date": "2011-03",
      "has_results": true,
      "last_update_posted_date": "2023-06-01",
      "last_synced_at": "2026-11-17T06:38:19.911Z",
      "location_count": 1,
      "location_summary": "Kansas City, Missouri",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01081223"
    },
    {
      "nct_id": "NCT07819396",
      "title": "Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Biphenotypic Leukemia",
        "Acute Leukemia",
        "Acute Leukemia of Ambiguous Lineage",
        "Acute Lymphoblastic Leukemia",
        "Acute Myeloid Leukemia",
        "Acute Undifferentiated Leukemia",
        "Blastic Plasmacytoid Dendritic Cell Neoplasm",
        "Burkitt Leukemia",
        "Burkitt Lymphoma",
        "Chronic Myeloid Leukemia, BCR-ABL1 Positive",
        "Lymphoblastic Lymphoma",
        "Mast Cell Leukemia",
        "Mixed Phenotype Acute Leukemia",
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Allogeneic CD34+-enriched and CD45RA-depleted PBSCs",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Aspiration",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Total-Body Irradiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE",
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 52,
      "start_date": "2027-01-01",
      "completion_date": "2031-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-14",
      "last_synced_at": "2026-11-17T06:38:19.911Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07819396"
    },
    {
      "nct_id": "NCT06239220",
      "title": "PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Cancer",
        "Head and Neck Squamous Cell Carcinoma",
        "Metastatic Head and Neck Cancer",
        "Recurrent Head and Neck Cancer",
        "Metastatic Head-and-neck Squamous-cell Carcinoma",
        "Recurrent Head and Neck Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "PD-L1 t-haNK",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cetuximab",
          "type": "DRUG"
        },
        {
          "name": "NAI",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2024-02-16",
      "completion_date": "2027-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-19",
      "last_synced_at": "2026-11-17T06:38:19.911Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06239220"
    },
    {
      "nct_id": "NCT03922724",
      "title": "Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Peripheral T-cell Lymphomas",
        "Lymphoproliferative Disorders",
        "Immune System Diseases"
      ],
      "interventions": [
        {
          "name": "ATL-RIC",
          "type": "DRUG"
        },
        {
          "name": "mRIC",
          "type": "DRUG"
        },
        {
          "name": "allo HCT",
          "type": "PROCEDURE"
        },
        {
          "name": "RIC",
          "type": "DRUG"
        },
        {
          "name": "GVHD prophylaxis",
          "type": "DRUG"
        },
        {
          "name": "IOC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "12 Years to 120 Years"
      },
      "enrollment_count": 118,
      "start_date": "2019-04-18",
      "completion_date": "2030-10-31",
      "has_results": false,
      "last_update_posted_date": "2026-11-09",
      "last_synced_at": "2026-11-17T06:38:19.911Z",
      "location_count": 2,
      "location_summary": "Bethesda, Maryland • Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03922724"
    },
    {
      "nct_id": "NCT04972942",
      "title": "Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "T-cell Acute Lymphoblastic Leukemia",
        "T-Cell Acute Lymphoblastic Lymphoma"
      ],
      "interventions": [
        {
          "name": "Daratumumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "New York Medical College",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "39 Years",
        "sex": "ALL",
        "summary": "Up to 39 Years"
      },
      "enrollment_count": 30,
      "start_date": "2023-05-22",
      "completion_date": "2028-09",
      "has_results": false,
      "last_update_posted_date": "2026-09-11",
      "last_synced_at": "2026-11-17T06:38:19.911Z",
      "location_count": 16,
      "location_summary": "Phoeniz, Arizona • Loma Linda, California • Los Angeles, California + 13 more",
      "locations": [
        {
          "city": "Phoeniz",
          "state": "Arizona"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04972942"
    }
  ]
}